Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WALKALS
2022-501624-14-00Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Ventoline (salbutamol) with Placebo (2 arms). Primary endpoints: Change from baseline in 6-minute walking test distance at month 3 and Change from baseline in 6-minute walking test distance at month 6. Started May 2023; status: terminated.
02
Drugs
salbutamol
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2022-501624-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501624-14-00.